These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

136 related items for PubMed ID: 24850456

  • 21. Pharmacoeconomic benefits of deferasirox in the management of iron overload syndromes.
    Imran F, Phatak P.
    Expert Rev Pharmacoecon Outcomes Res; 2009 Aug; 9(4):297-304. PubMed ID: 19670988
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Five Years of Deferasirox Therapy for Cardiac Iron in β-Thalassemia Major.
    Vlachaki E, Agapidou A, Spanos G, Klonizakis P, Vetsiou E, Mavroudi M, Boura P.
    Hemoglobin; 2015 Aug; 39(5):299-304. PubMed ID: 26177199
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Dose of deferasirox correlates with its effects, which differ between low-risk myelodysplastic syndrome and aplastic anaemia.
    Zhang R, Han B.
    J Clin Pharm Ther; 2022 Oct; 47(10):1619-1626. PubMed ID: 35748618
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Deferasirox therapy in children with Fanconi aplastic anemia.
    Tunç B, Tavil B, Karakurt N, Yarali N, Azik FM, Kara A, Culha V, Ozkasap S.
    J Pediatr Hematol Oncol; 2012 May; 34(4):247-51. PubMed ID: 22510772
    [Abstract] [Full Text] [Related]

  • 29. Deferasirox in MDS patients with transfusion-caused iron overload--a phase-II study.
    Metzgeroth G, Dinter D, Schultheis B, Dorn-Beineke A, Lutz K, Leismann O, Hehlmann R, Hastka J.
    Ann Hematol; 2009 Apr; 88(4):301-10. PubMed ID: 18758781
    [Abstract] [Full Text] [Related]

  • 30. Efficacy and safety of deferasirox compared with deferoxamine in sickle cell disease: two-year results including pharmacokinetics and concomitant hydroxyurea.
    Vichinsky E, Torres M, Minniti CP, Barrette S, Habr D, Zhang Y, Files B, study CICL670A2201 investigators.
    Am J Hematol; 2013 Dec; 88(12):1068-73. PubMed ID: 23946212
    [Abstract] [Full Text] [Related]

  • 31. Effect of deferasirox on iron overload in patients with transfusion-dependent haemoglobinopathies.
    Fragomeno C, Roccabruna E, D'Ascola DG.
    Blood Cells Mol Dis; 2015 Dec; 55(4):382-6. PubMed ID: 26460263
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. The deferiprone and deferasirox combination is efficacious in iron overloaded patients with β-thalassemia major: A prospective, single center, open-label study.
    Totadri S, Bansal D, Bhatia P, Attri SV, Trehan A, Marwaha RK.
    Pediatr Blood Cancer; 2015 Sep; 62(9):1592-6. PubMed ID: 25820920
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Profile of deferasirox for the treatment of patients with non-transfusion-dependent thalassemia syndromes.
    Ricchi P, Marsella M.
    Drug Des Devel Ther; 2015 Sep; 9():6475-82. PubMed ID: 26719673
    [Abstract] [Full Text] [Related]

  • 39. Pharmacokinetics and safety of deferasirox in subjects with chronic kidney disease undergoing haemodialysis.
    Maker GL, Siva B, Batty KT, Trengove RD, Ferrari P, Olynyk JK.
    Nephrology (Carlton); 2013 Mar; 18(3):188-93. PubMed ID: 23332024
    [Abstract] [Full Text] [Related]

  • 40. Safety of deferasirox: a retrospective cohort study on the risks of gastrointestinal, liver and renal events.
    Huang WF, Chou HC, Tsai YW, Hsiao FY.
    Pharmacoepidemiol Drug Saf; 2014 Nov; 23(11):1176-82. PubMed ID: 24946110
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.